English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Jose Luis Górriz, MD, Servicio de Nefrología, Hospital Dr. Peset, Avda Gaspar Aguilar, 90, E-46017 Valencia (Spain) Dear Sir, Gemfibrozil is a fibric acid derivative introduced in 1982 as a lipid-lowering drug. Adverse effects such as myopathy [1], myosi-tis [2] and rhabdomyolysis [3, 4] have been reported when it is administered in conjunction with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, and infrequent acute renal failure has also been published with this drug combination [5-7]. Preexisting mild renal impairment may increase the risk of rhabdomyolysis since the primary route of elimination of gemfibrozil is renal. We report a case of rhabdomyolysis and acute renal failure in a patient receiving gemfibrozil as the only lipidlowering agent, and in absence of any other drug or clinical condition recognized as cause of rhabdomyolysis. Material and Methods: The patient was a 70-year-old woman with a 12-year history of insulin-dependent diabetes mellitus, and in the last 7 years hypertension, currently in good control with enalapril 20 mg daily. The previous laboratory data to gemfibrozil treatment showed: plasma urea 25 mmol/l (71 mg/dl), plasma creatinine 159 mmol/l (1.8 mg/dl), hemoglobin 131 g/l, hematocrit 38.7%. The fasting lipid status showed: total plasma cholesterol 7.33 mmol/l (283 mg/dl), plasma triglyceride 3.45 mmol/l (305 mg/dl), plasma LDL-cholesterol 4.76 mmol/l (184 mg/dl), plasma HDL-cholesterol 0.95 mmol/ 1 (37 mg/dl). Due to the inefficacy of dietary treatment to control hyperlipidemia during a 3-month period, gemfibrozil was administered at a dose of 600 mg twice a day. Four days later she complained of generalized muscle weakness and tenderness in lower extremities and lumbar region, with emission of dark urine. Diclofenac 75 mg daily was added, and 48 h later the patient became oliguric. At admission, the patient appeared unwell. The temperature was 36.5°C and the blood pressure was 170/85 mm Hg. Tenderness in the lower extremities and lumbar region were detected on physical examination. Laboratory data showed: plasma urea 75.3 mmol/l (211 mg/dl), plasma creatinine 548 μmol/l (6.2 mg/dl), potassium 5.9 mmol/ 1, sodium 137 mmol/l, calcium 2.44 mmol/l (9.8 mg/dl), total proteins 7.1 g/dl, glucose 6.66 mmol/l (120 mg/dl), pH 7.27, carbon dioxide 18 mmol/l, creatine kinase (CK) 719 μmol/l (43,173 IU/1), CK-MB 2%, aspartate aminotransferase 15.2 μkat/1 (912 U/l), aldo-lase 17 IU/L (ref. < 7.6), lactate dehydroge-nase 47.2 μkat/1 (2,836

Rhabdomyolysis and Acute Renal Failure Associated with Gemfibrozil Therapy